C21 Investments Inc. is an integrated cannabis company that cultivates, processes, and sells cannabis and hemp-derived products in the U.S. A key strength is its gross margin of 41.7%, indicating efficient production; however, concerns arise from a negative net margin of -9.9% and low ROE of -12.8%, suggesting profitability challenges. The current ratio of 1.30 reflects adequate liquidity, but a quick ratio of 0.58 raises questions about short-term financial health. Overall, while the company shows potential, it faces significant profitability hurdles.
Loading financial metrics...
Debt of $10.5M is 4.7x the company's cash position of $2.2M.
Exceptional revenue growth of 38.7% YoY demonstrates strong market demand and competitive positioning.
Operating cash flow surged 115.7% YoY, indicating strong cash generation capability.
Free cash flow increased 183.9% YoY, enhancing capital allocation optionality.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-FY (March 31, 2026)